Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump
Publishing timestamp: 2024-01-23 09:43:26
Summary
Johnson & Johnson reported fourth-quarter earnings and revenue that slightly exceeded Wall Street's expectations. Sales in the company's pharmaceutical and medical devices businesses saw significant growth. J&J provided full-year guidance for 2024, forecasting sales and adjusted earnings per share. The company's medical devices business and pharmaceutical division both contributed to the positive results. J&J expects continued growth in these areas, driven by factors such as increased demand for nonurgent surgeries and the success of certain drugs. The article also mentions J&J's involvement in Medicare drug price negotiations and ongoing legal concerns related to talc-based products.
Sentiment: NEUTRAL
Tickers: UNDEFINED, ABBV, JNJ,
Keywords: abbvie inc, business news, johnson & johnson, breaking news, earnings, biotech and pharmaceuticals, joe biden, business, biotechnology, pharmaceuticals, health care industry, kenvue inc,
Source: https://www.cnbc.com/2024/01/23/johnson-johnson-jnj-earnings-q4-2023.html